T-Cell Immunotherapy Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

T-Cell Immunotherapy Market: By Modality Type (Research and Commercialized), Therapy Type (CAR T-Cell Therapy, T Cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes (TIL)-based), Indication Type (Lymphoma, Leukemia, Myeloma, Melanoma, Brain & Central Nervous System, Liver Cancer, and Others) and geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

T-Cell Immunotherapy Market size is expected to be valued at USD 4,923.2 million in 2022, which is expected to grow at a CAGR of 18.2% over 2022-2028. T-cell immunotherapy is a kind of immunotherapy that makes the immune cells to b able to attack better on cancer. There are two essential kinds of T-cell immunotherapy: CAR T-cell therapy and tumor-infiltrating lymphocytes (or TIL) therapy. Both include collecting the body’s immune cells, budding vast numbers of these cells in the laboratory, and then giving these cells back to the body through a needle in your vein. T-cell transfer therapy is also known as adoptive cell therapy, immune cell therapy, and immunotherapy. The growth in investment in T-cell immunotherapy methods of disease treatment can lead to the development of the T-cell immunotherapy market. Moreover, technological advancements in production processes and advances in CAR T-cell immunotherapy for solid tumors are primary factors that can boost the global T-cell immunotherapy market. Apart from these, clinical success and approvals of Kymriah and Yescarta unlocked encouraging and new roads for inventors of cellular immunotherapies, which can also accelerate the market in the future. However, some factors, such as the absence of skilled professionals, the high investment required for therapy growth, and the absence of standard therapy procedures can restrain the market growth. The rising demand for gene editing and cell therapies, in addition to the high mortality rates and the increasing number of clinical trials, can create an opportunity for the growth of the global T-cell immunotherapy market. Moreover, the government is focusing on awareness about health consciousness in the rising cancer patients and geriatric population, which will provide lucrative market growth.

Key Developments:

In May 2022, a clinical supply agreement was announced between Harpoon Therapeutics and F. Hoffmann-La Roche Ltd (Roche) to provide atezolizumab (Tecentriq®) for usage in the clinical development program

In October 2021, Takeda Pharmaceutical Company Limited acquired GammaDelta Therapeutics Limited to expand its business.

T-Cell Immunotherapy Market

MARKET SUMMARY
-
18.2%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 18.2%
  • Largest Market– North America
  • Fastest Growing Market– Europe

T-Cell Immunotherapy Market

  • The T-cell immunotherapy market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The T-cell immunotherapy market is segmented based on modality type, therapy type, indication type and geography.
Key Players
  • Novartis AG
  • Merck KGaA
  • Gilead Sciences Inc.
  • TCR2 Therapeutics Inc
  • Bluebird Bio Inc.
T-Cell Immunotherapy Market Dynamics

One of the primary reasons for the growth of the global T-cell immunotherapy market is the increasing prevalence of cancer and a growing diversity of patients with failed responses to various treatments. Moreover, the rising cancer cases in pediatric and geriatric patients are likely to result in higher demand for a reliable and efficient treatment method for the enhancement of the quality of life of the patient. Moreover, increasing government activities for enhancing healthcare insurance outlines and progression in research and development activities are expected to propel the market’s growth in the forecast period.


North America Got Significant Share

T-Cell Immunotherapy Market

North America is dominating the global T-cell immunotherapy market due to the growing number of regulatory sanctions in Canada and the U.S., accompanied by the altering reimbursement scenario. Moreover, an increase in research and development activities in the biotechnology and pharmaceutical sector, along with a commercial base together with a vast number of clinical trials being directed for T-cell therapies in the U.S, have also contributed to the growth of the market.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
T-Cell Immunotherapy Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The T-cell immunotherapy market is projected to expand at a CAGR of 18.2% during the forecast period

Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc, Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, Celgene Corporation

 

North-America is the fastest-growing region for T-cell immunotherapy market


Report

Table Of Content

1. Executive Summary
2. Global T-Cell Immunotherapy Market Introduction
2.1. Global T-Cell Immunotherapy Market – Taxonomy
2.2. Global T-Cell Immunotherapy Market –Definitions
2.2.1. Modality Type
2.2.2. Therapy Type
2.2.3. Indication Type
2.2.4. By Region
3. Global T-Cell Immunotherapy Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global T-Cell Immunotherapy Market Dynamic Factors – Impact Analysis
3.6. Global T-Cell Immunotherapy Market – Competition Landscape
3.7. Epidemiology
4. Global T-Cell Immunotherapy Market Analysis, 2017-2021 and Forecast, 2022-2028
4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global T-Cell Immunotherapy Market, By Modality Type, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1. Research
5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Commercialized
5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6. Global T-Cell Immunotherapy Market, By Therapy Type, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1. CAR T-Cell Therapy
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. T Cell Receptor (TCR)-based
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Tumor Infiltrating Lymphocytes (TIL)-based
6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global T-Cell Immunotherapy Market, By Indication Type, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1. Lymphoma
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Leukemia
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Myeloma
7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Melanoma
7.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Brain & Central Nervous System
7.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Liver Cancer
7.6.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.6.3. Market Opportunity Analysis
7.7. Other
7.7.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.7.3. Market Opportunity Analysis
8. Global T-Cell Immunotherapy Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global T-Cell Immunotherapy Market – Opportunity Analysis Index, By Modality Type, By Therapy Type, By Indication Type, and Region, 2022-2028
9. North America T-Cell Immunotherapy Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.1. Modality Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Research
9.1.2. Commercialized
9.2. Therapy Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. CAR T-Cell Therapy
9.2.2. T Cell Receptor (TCR)-based
9.2.3. Tumor Infiltrating Lymphocytes (TIL)-based
9.3. Indication Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Lymphoma
9.3.2. Leukemia
9.3.3. Myeloma
9.3.4. Melanoma
9.3.5. Brain & Central Nervous System
9.3.6. Liver Cancer
9.3.7. Others
9.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America T-Cell Immunotherapy Market – Opportunity Analysis Index, By Modality Type, By Therapy Type, By Indication Type, and Country, 2022-2028
9.6. North America T-Cell Immunotherapy Market Dynamics – Trends
10. Europe T-Cell Immunotherapy Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
10.1. Modality Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Research
10.1.2. Commercialized
10.2. Therapy Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. CAR T-Cell Therapy
10.2.2. T Cell Receptor (TCR)-based
10.2.3. Tumor Infiltrating Lymphocytes (TIL)-based
10.3. Indication Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Lymphoma
10.3.2. Leukemia
10.3.3. Myeloma
10.3.4. Melanoma
10.3.5. Brain & Central Nervous System
10.3.6. Liver Cancer
10.3.7. Others
10.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe T-Cell Immunotherapy Market – Opportunity Analysis Index, By Modality Type, By Therapy Type, By Indication Type, and Country, 2022-2028
10.6. Europe T-Cell Immunotherapy Market Dynamics – Trends
11. Asia-Pacific T-Cell Immunotherapy Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
11.1. Modality Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Research
11.1.2. Commercialized
11.2. Therapy Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. CAR T-Cell Therapy
11.2.2. T Cell Receptor (TCR)-based
11.2.3. Tumor Infiltrating Lymphocytes (TIL)-based
11.3. Indication Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Lymphoma
11.3.2. Leukemia
11.3.3. Myeloma
11.3.4. Melanoma
11.3.5. Brain & Central Nervous System
11.3.6. Liver Cancer
11.3.7. Others
11.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific T-Cell Immunotherapy Market – Opportunity Analysis Index, By Modality Type, By Therapy Type, By Indication Type, and Country, 2022-2028
11.6. Asia-Pacific T-Cell Immunotherapy Market Dynamics – Trends
12. Latin America T-Cell Immunotherapy Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
12.1. Modality Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Research
12.1.2. Commercialized
12.2. Therapy Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. CAR T-Cell Therapy
12.2.2. T Cell Receptor (TCR)-based
12.2.3. Tumor Infiltrating Lymphocytes (TIL)-based
12.3. Indication Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Lymphoma
12.3.2. Leukemia
12.3.3. Myeloma
12.3.4. Melanoma
12.3.5. Brain & Central Nervous System
12.3.6. Liver Cancer
12.3.7. Others
12.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America T-Cell Immunotherapy Market – Opportunity Analysis Index, By Modality Type, By Therapy Type, By Indication Type, and Country, 2022-2028
12.6. Latin America T-Cell Immunotherapy Market Dynamics – Trends
13. Middle East and Africa T-Cell Immunotherapy Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
13.1. Modality Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Research
13.1.2. Commercialized
13.2. Therapy Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. CAR T-Cell Therapy
13.2.2. T Cell Receptor (TCR)-based
13.2.3. Tumor Infiltrating Lymphocytes (TIL)-based
13.3. Indication Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Lymphoma
13.3.2. Leukemia
13.3.3. Myeloma
13.3.4. Melanoma
13.3.5. Brain & Central Nervous System
13.3.6. Liver Cancer
13.3.7. Others
13.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. South Africa
13.4.3. Rest of MEA
13.5. MEA T-Cell Immunotherapy Market- Opportunity Analysis Index, By Modality Type, By Therapy Type, By Indication Type, and Country, 2022-2028
13.6. MEA T-Cell Immunotherapy Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Key Modality Types, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Novartis AG
14.2.2. Merck KGaA
14.2.3. Gilead Sciences Inc.
14.2.4. TCR2 Therapeutics Inc
14.2.5. Bluebird Bio Inc.
14.2.6. Sorrento Therapeutics
14.2.7. Fate Therapeutics
14.2.8. Pfizer Inc.
14.2.9. Amgen
14.2.10. Celgene Corporation
15. Research Methodology
16. Key Assumptions and Acronyms

Report

Company Profile

  • Novartis AG
  • Merck KGaA
  • Gilead Sciences Inc.
  • TCR2 Therapeutics Inc
  • Bluebird Bio Inc.
  • Sorrento Therapeutics
  • Fate Therapeutics
  • Pfizer Inc.
  • Amgen
  • Celgene Corporation

Description

T-Cell Immunotherapy Market size is expected to be valued at USD 4,923.2 million in 2022, which is expected to grow at a CAGR of 18.2% over 2022-2028. T-cell immunotherapy is a kind of immunotherapy that makes the immune cells to b able to attack better on cancer. There are two essential kinds of T-cell immunotherapy: CAR T-cell therapy and tumor-infiltrating lymphocytes (or TIL) therapy. Both include collecting the body’s immune cells, budding vast numbers of these cells in the laboratory, and then giving these cells back to the body through a needle in your vein. T-cell transfer therapy is also known as adoptive cell therapy, immune cell therapy, and immunotherapy. The growth in investment in T-cell immunotherapy methods of disease treatment can lead to the development of the T-cell immunotherapy market. Moreover, technological advancements in production processes and advances in CAR T-cell immunotherapy for solid tumors are primary factors that can boost the global T-cell immunotherapy market. Apart from these, clinical success and approvals of Kymriah and Yescarta unlocked encouraging and new roads for inventors of cellular immunotherapies, which can also accelerate the market in the future. However, some factors, such as the absence of skilled professionals, the high investment required for therapy growth, and the absence of standard therapy procedures can restrain the market growth. The rising demand for gene editing and cell therapies, in addition to the high mortality rates and the increasing number of clinical trials, can create an opportunity for the growth of the global T-cell immunotherapy market. Moreover, the government is focusing on awareness about health consciousness in the rising cancer patients and geriatric population, which will provide lucrative market growth.

Key Developments:

In May 2022, a clinical supply agreement was announced between Harpoon Therapeutics and F. Hoffmann-La Roche Ltd (Roche) to provide atezolizumab (Tecentriq®) for usage in the clinical development program

In October 2021, Takeda Pharmaceutical Company Limited acquired GammaDelta Therapeutics Limited to expand its business.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX